Introduction {#s1}
============

Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative disease in Western populations, and it is characterized by its clinical and genetic heterogeneity. [@B10] described the widely used cytogenetic classification of CLL based on the most prevalent chromosomal aberrations in the CLL genome ([@B10]), that is, trisomy 12 and deletions in 13q14.2--14.3, 11q22.3, and 17p13.1. Since that moment, new genome-wide studies have revealed new recurrent genomic aberrations, such as trisomy 19, amplifications at 2p and 8q, and deletions at 8p, 6q21, 18p, and 20p ([@B35]; [@B21]). Similarly, a wealth of genomic and epigenomic modulators of CLL's clinical aggressivity have been discovered ([@B32]), such as point mutations in *NOTCH1, SF3B1, ATM, TP53*, and *POT1* and the absence of somatic hypermutation at the *IGHV* locus. It has been observed that copy number aberrations (CNAs) in CLL genomes tend to be acquired early in disease evolution and usually remain stable, whereas the mutational heterogeneity can increase ([@B32]). Indeed, mounting evidence indicates that the accumulation of these cytogenomic events modulates CLL proliferation and clinical aggressivity to a great extent ([@B39]; [@B12]), acting as drivers of genomic complexity and clonal evolution ([@B11]; [@B48]; [@B15]) and accumulating in relapsed cases ([@B27]; [@B24]).

CNAs and copy number neutral loss of heterozygosity (CNN-LOH) are oncogenic mechanisms that induce gene-dosage effects, disrupt coding sequences, cause structural rearrangements, or potentiate epigenetic effects. Oncogenes are frequently affected by copy number gains, while tumor suppressor genes tend to be deleted. Massive array-based techniques such as array comparative genomic hybridization and single-nucleotide polymorphism (SNP) arrays have enabled the analysis of structural aberrations on cancer genomes to an unprecedented resolution of 10--100 kb. With the development of massive sequencing technologies, large databases of cancer sequence data have been published. This motivated the development of a variety of CNA detection algorithms from exome-sequencing data, which have the additional benefit of detecting smaller CNA events at the expense of increased false discoveries and reduced sensitivity and specificity ([@B33]). These methods are specifically designed to face particular issues, particularly those inherent to the sequencing protocol (such as biases induced by hybridization, GC content, and read mappability), due to cancer biology (ploidy estimation and subclonality) ([@B51]) and due to the presence or absence of matched controls ([@B19]).

In this analysis, we used previously published exome-seq data in order to detect small recurrent structural events involved in the pathogenesis of CLL. Our results not only reproduce the known cytogenetic aberrations in CLL but also support the existence of multiple recurrent focal CNAs and CNN-LOH affecting key oncogenic pathways, some of which are clearly associated with higher proliferative capacity, shorter survival, and altered gene expression. We conclude that focal CNAs may be more relevant than previously expected in the pathogenesis of CLL, and they merit further consideration for prognostic stratification.

Methodology {#s2}
===========

Data Source {#s2_1}
-----------

The *International Cancer Genome Consortium* (ICGC) Data Access Committee granted us access to the CLL sequencing data ([@B38]) deposited in the *European Genome-Phenome Database* (EGA) under *DACO-1040945*. For this analysis, we used exome-seq data from matched control and tumor samples of CLL cases under the accession code *EGAD00001001464*. Patient characteristics can be consulted in [**Table 1**](#T1){ref-type="table"}.

###### 

Patient characteristics.

  Patient characteristics   
  ------------------------- -------------
  Number of cases           441
  Males/females             59.7%/40.3%
  Median age at diagnosis   62.5 years
  \% of MBL                 11.20%
  \% of Binet A             77.12%
  \% of Binet B             9.61%
  \% of Binet C             2.06%
  \% unmutated IGHV         35.03%

MBL, monoclonal B-cell lymphocytosis.

Data Preprocessing {#s2_2}
------------------

Samples were processed by Puente et al. (2015) as described in their original paper ([@B36]). Briefly, 3 μg of genomic DNA was used for paired-end sequencing library construction, followed by enrichment in exomic sequences using the *SureSelect Human All Exon 50Mb* kit (Agilent Technologies). Next, DNA was pulled down using magnetic beads with streptavidin, followed by 18 cycles of amplification. Sequencing was performed on an Illumina GAIIx or on a HiSeq2000 sequencer (2 × 76 bp). Exome-seq data were aligned to the reference genome (GRCh37.75) using *bwa* ([@B25]). Duplicate read removal, sorting, and indexing were done using *samtools* ([@B26]). Base quality score recalibration was made with *BamUtil* ([@B5]) using a logistic regression model.

CNA and CNN-LOH Detection {#s2_3}
-------------------------

We analyzed paired tumor-normal exome-sequencing data with Control-FREEC version 11.3 in order to identify somatic CNA and CNN-LOH regions ([@B4]). Control-FREEC uses aligned reads to construct and normalize a copy number profile and a B-allele frequency (BAF) profile. Then, it performs profile segmentation and infers genotype status for each segment using both copy number and allelic frequency information. Finally, genomic aberrations are identified and annotated.

The following specifications were used: "window = 0," "ploidy = 2," "breakPointThreshold = 1.2," "noisyData = TRUE," "readCountThreshold = 50," "forceGContentNormalization = 1," "contaminationAdjustment = TRUE," "telocentromeric = 50000," and "mateOrientation = 0." BAFs were estimated using all variants reported in dbSNP (version 150) with a minimal coverage per variant position of 5 reads and a minimal sequencing quality per position of 20 Phred. Variant calling was limited to regions covered in the SureSelect Exome Capture 50Mb version 4 kit.

LOH and CNA Selection and Filtering {#s2_4}
-----------------------------------

CNN-LOH were called with p-values \< 0.05 (Kolmogorov--Smirnov test) and an uncertainty upper threshold of 5%. Regions with lowmappability according to UCSC 75-bp mappability tracks (score below 0.5) were filtered out. As expected, we observed regions that seemed prone to CNA erroneous detection. Thus, we decided to apply a hard filter and discard those CNAs significantly enriched in both amplifications and deletions, as well as those located near a telomeric or centromeric region. CNA events were detected using GISTIC2.0 ([@B2]). GITIC2.0 was run with default parameters plus the arm peel-off filter. Focal recurrent CNAs were defined as those spanning less than 50% of a chromosome arm with a residual *q*-value \< 0.05 and a wide peak size below 10 megabases. A 1 − log2 tumor/normal ratio above 0.3 was used to define amplifications, and a ratio below −0.3 was used to define deletions.

Survival Analysis {#s2_5}
-----------------

Variables associated with time to treatment (TTT) and overall survival (OS) were analyzed using Cox regression as implemented in the *survival* R package ([@B45]; [@B37]; [@B44]). Assessment of the proportional hazards assumption was performed using the *cox.zph* function. We created two different models: a univariate model that only includes CNA status for each gene and an adjusted model that included variables associated with clinical outcome at a *p*-value \< 0.2 in a univariate model. The combined model (CM) for TTT analysis included as covariates donor sex, stage at diagnosis (monoclonal B-cell lymphocytosis (MBL), Binet A, Binet B, and Binet C), and *IGHV* mutational status, while the CM for OS analysis included stage at diagnosis, *IGHV* mutation status, and age at diagnosis. The Benjamini--Hochberg (BH) method was used to adjust for multiple testing.

RNAseq Analysis and Correlation With CNA Status {#s2_6}
-----------------------------------------------

Two hundred twenty patients had matched RNAseq data of CLL-purified cells (accession IDs *EGAD00001001443* and *EGAD00001000258*). Illumina adapters were removed using *cutadapt* ([@B30]), and alignment to the human reference genome (GRCh37) was performed using *Hisat2* ([@B18]) with default specifications. We used the *Hisat2*-provided Hierarchical Graph FM index for GRCh37 with SNP and Ensembl transcript information. Bam files were sorted and indexed using *samtools* ([@B26]). Bam files were processed in *R* ([@B37]) according to the RNAseq gene expression protocol developed by [@B28]. Briefly, bam files were read using *Rsamtools* ([@B31]), followed by gene-level expression estimation using the *SummarizeOverlaps* function from the *GenomicAlignments* package ([@B22]). Gene models in GTF format were downloaded from Ensembl (GRCh37.75 version) ([@B47]). A log2-transformation on normalized frames per kilobase counts was performed. Focal CNAs were classified according to Gistic into low-range events (tumor/normal log2 ratio \> 0.3 and \<0.9 for amplifications and less than −0.9 and more than −0.3 for deletions) and higher-range events (tumor/normal log2 ratio \> 0.9 for amplifications and less than −0.9 for deletions). Correlation between CNA status and gene expression was performed using Spearman's correlation. A minimum of 5 CNA events with matched transcriptomic data was set for analysis. Furthermore, immunoglobulin and T-cell receptor gene rearrangements were not included. *p*-values were adjusted for multiple testing using the BH method.

Results {#s3}
=======

Focal CNA Regions and Their Association With TTT and OS {#s3_1}
-------------------------------------------------------

We identified 54 recurrent focal CNAs in the CLL genome (residual *q*-value \< 0.05, [**Supplemental Figure 1**](#SM1){ref-type="supplementary-material"}, [**Table 2**](#T2){ref-type="table"}). Among them, there were 31 recurrent amplifications with a wide peak size of 75.1 kb ([**Figure 1**](#f1){ref-type="fig"}) and 23 recurrent deletions with a median wide peak size of 405 kb ([**Figure 2**](#f2){ref-type="fig"}).

###### 

Recurrent focal amplifications and deletions in the chronic lymphocytic leukemia (CLL) genome, including their frequency, wide peak region, length, q-value, residual *q*-value, and involved genes.

  Unique Name             Cases   Cytoband   Wide Peak Boundaries         Length      Q value     Residual Q value   Genes in Wide Peak
  ----------------------- ------- ---------- ---------------------------- ----------- ----------- ------------------ -------------------------------------------------------------------------------------------------------
  Amplification Peak 3    9       1p31.1     chr1:74500015--74621552      1.22E+05    4.80E−16    1.86E−11           *LRRIQ3, FPGT, TNNI3K*
  Amplification Peak 4    9       1p22.2     chr1:91784576--91813183      2.86E+04    3.13E−11    5.32E−09           *HFM1*
  Amplification Peak 8    11      1q25.2     chr1:176093431--176153873    6.04E+04    2.73E−13    8.89E−06           *RFWD2*
  Amplification Peak 9    3       1q42.12    chr1:225152123--225211696    59,573      1.71E−03    1.71E−03           *DNAH14*
  Amplification Peak 14   15      3q25.1     chr3:149563840--149684409    120,569     4.78E−04    1.92E−03           *PFN2, RNF13*
  Amplification Peak 15   14      3q29       chr3:195053676--195063318    9.64E+03    1.01E−05    1.72E−05           *ACAP2*
  Amplification Peak 17   6       4p16.3     chr4:3449609--3495293        45,684      9.11E−04    9.11E−04           *HGFAC, DOK7*
  Amplification Peak 18   5       4p15.2     chr4:26622159--26641959      19,800      0.01        0.01               *TBC1D19*
  Amplification Peak 19   5       4q31.21    chr4:145658875--146010087    351,212     5.17E−03    5.17E−03           *ANAPC10, HHIP*
  Amplification Peak 20   10      5q35.3     chr5:180052785--180167076    1.14E+05    1.68E−05    1.68E−05           *FLT4, OR2Y1*
  Amplification Peak 22   4       6q15       chr6:89479426--89563571      84,145      1.47E−04    1.47E−04           *RNGTT*
  Amplification Peak 24   70      7p14.1     chr7:38284691--38357086      7.24E+04    1.62E−82    1.62E−82           *TCRG locus*
  Amplification Peak 28   19      8q24.13    chr8:124810460--124812196    1,736       2.36E−03    0.02               *FAM91A1*
  Amplification Peak 30   6       9q34.3     chr9:138905634--139092618    186,984     0.03        0.03               *LHX3, C9orf69, NACC2*
  Amplification Peak 31   8       9q34.3     chr9:140161390--140246050    84,660      1.71E−03    1.71E−03           *COBRA1, C9orf167, EXD3, NRARP*
  Amplification Peak 32   6       10q24.33   chr10:105073962--105140579   66,617      1.28E−04    1.28E−04           *TAF5, PCGF6*
  Amplification Peak 33   26      11p13      chr11:32676388--32705141     2.88E+04    7.50E−13    5.84E−12           *CCDC73, WT1*
  Amplification Peak 34   2       11p11.2    chr11:45935717--45955761     20,044      0.04        0.04               *PEX16, PHF21A, GYLTL1B*
  Amplification Peak 40   11      13q13.3    chr13:35622613--35697715     75,102      5.17E−03    5.17E−03           *NBEA*
  Amplification Peak 41   4       13q22.1    chr13:73530979--73643032     112,053     0.01        0.01               *KLF5, PIBF1*
  Amplification Peak 42   188     14q11.2    chr14:22749319--22925867     1.77E+05    4.44E−186   2.84E−185          *TCRA locus*
  Amplification Peak 45   12      14q32.33   chr14:105059814--105172511   1.13E+05    2.70E−05    4.01E−04           *INF2, TMEM179, MIR4710, AKT1*
  Amplification Peak 50   8       16q22.1    chr16:66819728--66824959     5.23E+03    5.54E−05    5.54E−05           *CCDC79, NAE1*
  Amplification Peak 51   12      17q11.2    chr17:30228618--30321772     9.32E+04    2.72E−20    2.23E−17           *SUZ12, UTP6*
  Amplification Peak 53   6       17q25.3    chr17:79389937--79430022     40,085      0.02        0.02               *hsa-mir-3186, BAHCC1, MIR3186*
  Amplification Peak 54   7       18q11.2    chr18:21229308--21329567     100,259     0.02        0.02               *LAMA3, ANKRD29*
  Amplification Peak 55   15      18q22.1    chr18:66365105--66377388     12,283      0.03        0.03               *TMX3*
  Amplification Peak 57   8       19p12      chr19:20221949--20317969     96,020      0.02        0.03               *ZNF90, ZNF486*
  Amplification Peak 59   3       20q13.12   chr20:42694274--42813092     118,818     5.94E−03    5.94E−03           *JPH2, TOX2*
  Amplification Peak 62   5       20q13.33   chr20:62705116--62831313     126,197     0.02        0.02               *NPBWR2, MYT1, OPRL1, RGS19, C20orf201*
  Amplification Peak 66   4       22q13.33   chr22:50967459--51008050     40,591      1.39E−03    1.39E−03           *CPT1B, TYMP, KLHDC7B, CHKB-CPT1B, ODF3B, SYCE3*
  Deletion Peak 7         193     2p11.2     chr2:88894337--95722218      6,827,881   0           0                  *IGK locus*
  Deletion Peak 8         4       2q23.3     chr2:152234651--152663572    428,921     0.04        0.04               *NEB, RIF1*
  Deletion Peak 13        12      3q25.33    chr3:159713418--160118695    405,277     0.02        0.04               *IFT80, C3orf80, IL12A*
  Deletion Peak 16        19      4q13.2     chr4:69344747--69691521      3.47E+05    7.11E−06    3.92E−05           *UGT2B15, UGT2B17*
  Deletion Peak 17        8       4q13.3     chr4:70897589--71020148      122,559     0.02        0.02               *HTN1, CSN1S2AP, CSN1S2BP*
  Deletion Peak 18        9       4q21.23    chr4:84367119--84457735      90,616      1.71E−03    6.90E−03           *MRPS18C, FAM175A*
  Deletion Peak 21        15      6q21       chr6:110797012--111583801    786,789     1.74E−04    1.74E−04           *AMD1, CDK19, RPF2, GTF3C6, SLC16A10, GSTM2P1*
  Deletion Peak 23        12      7p22.1     chr7:5269419--5920366        650,947     0.02        0.02               *hsa-mir-589, ACTB, FSCN1, RNF216, FBXL18, TNRC18, SLC29A4, ZNF815*
  Deletion Peak 24        11      7q21.2     chr7:92147625--92247368      9.97E+04    3.11E−05    9.98E−05           *RBM48, MGC16142, FAM133B, LOC728066, CDK6*
  Deletion Peak 27        11      8q22.1     chr8:95690341--95840099      149,758     0.02        0.02               *DPY19L4, ESRP1, TP53INP1*
  Deletion Peak 29        3       9p21.2     chr9:26116211--27109465      993,254     1.62E−03    1.62E−03           *PLAA, LRRC19, C9orf82, IFT74, TEK*
  Deletion Peak 32        33      11q14.3    chr11:89185111--89443615     2.59E+05    1.36E−34    1.06E−22           *FOLH1B, NOX4*
  Deletion Peak 34        44      11q22.3    chr11:110018375--110449975   4.32E+05    1.18E−31    1.13E−18           *FDX1, RDX, ATM*
  Deletion Peak 37        12      12q24.33   chr12:132335406--132436802   101,396     1.09E−03    1.05E−03           *ULK1, PUS1*
  Deletion Peak 38        200     13q14.2    chr13:50306479--51501752     1,195,273   0           0                  *hsa-mir-15a, DLEU2, TRIM13, DLEU1, SPRYD7, ST13P4, DLEU7, CTAGE10P, KCNRG, MIR15A, MIR16-1, MIR3613*
  Deletion Peak 40        41      14q21.1    chr14:39721874--39871082     1.49E+05    1.56E−18    3.83E−10           *CTAGE5, LOC100288846, MIA2, FBXO33*
  Deletion Peak 42        27      14q32.33   chr14:104506663--105201322   6.95E+05    1.61E−11    1.05E−03           *hsa-mir-203, KIF26A, INF2, ASPG, TMEM179, C14orf180, MIR203, MIR3545, MIR4710*
  Deletion Peak 43        33      14q32.33   chr14:105861125--107349540   1.49E+06    1.89E−13    6.44E−08           *CRIP1, CRIP2, ELK2AP, ADAM6, MTA1, KIAA0125, TMEM121, C14orf80, LINC00226, LINC00221, TEX22*
  Deletion Peak 46        10      15q15.1    chr15:42138836--42192730     53,894      3.47E−03    0.01               *hsa-mir-4310, SPTBN5, MIR4310*
  Deletion Peak 49        2       16q12.2    chr16:53968071--55360473     1,392,402   0.01        0.01               *IRX5, IRX3, CRNDE*
  Deletion Peak 54        8       18q21.1    chr18:43604458--43796648     192,190     0.04        0.04               *ATP5A1, HAUS1, PSTPIP2*
  Deletion Peak 55        10      18q23      chr18:77246915--77733812     486,897     2.64E−04    2.84E−04           *CTDP1, KCNG2, PQLC1, HSBP1L1, NFATC1*
  Deletion Peak 66        125     22q11.22   chr22:23162356--23404171     2.42E+05    2.71E−277   5.01E−277          *IGL locus*

![Representation of the focal amplifications detected in the chronic lymphocytic leukemia (CLL) genomes along with their corresponding statistical significance.](fgene-10-00854-g001){#f1}

![Representation of the focal deletions detected in the chronic lymphocytic leukemia (CLL) genomes along with their corresponding statistical significance.](fgene-10-00854-g002){#f2}

The most frequently amplified regions were found in 11p13 (adjacent to the *WT1* locus), 8q24.13 (*FAM91A1*), 3q25.1 (*PFN2* and *RNF13*), 18q22.1 (*TMX3*), 3q29 (*ACAP2*), 17q11.2 (*SUZ12*), 14q32.33 (adjacent to the *AKT1* locus), 13q13.3 (*NBEA/BCL8B*), 1q25.2 (*RFWD2*), 5q35.3 (*FLT4*), 19p13.3 (adjacent to the *APC2* locus), 1p22.2 (*HFM1*), and 1p31.1. Similarly, the most recurrent focal deletions were detected in 13q14.2 (*DLEU1* locus), 11q22.3 (*ATM* locus), 14q21.1 (*MIA2*), 11q14.3 (*NOX4*), 14q32.33 (*IGH* locus), and 4q13.2 (*UGT2B15* and *UGT2B17* loci). Moreover, we observed frequent deletions of immunoglobulin loci and recurrent amplified regions at TCR genes, likely reflecting deletions present in the T lymphocytes within control samples.

Three focal deletions were associated with TTT (BH *q*-value \< 0.05): 11q22.3 (*ATM* locus), 14q32.33 (*IGH* locus), and 7q21.2 (*CDK6* locus). 11q22.3 loss was associated with shorter survival too. No event was associated with TTT or OS after adjusting for *IGHV* status, sex, and disease stage (BH *q*-value \< 0.05). No recurrent gain was associated with treatment-free survival or OS. The association results can be consulted in [**Supplementary Table 1**](#SM2){ref-type="supplementary-material"}.

Furthermore, *SETD2* deletions (nine cases) and *IRF4* gains (five cases) were nearly significant (GISTIC residual *q*-values of 0.08 and 0.06, respectively) and associated with clinical evolution. *SETD2* deletion was associated with shorter treatment free survival (*p*-value 1.3 × 10^−8^) independent of *IGHV* status, sex, and disease stage (*p*-value 2.3 × 10^−3^); and it was also associated with shorter survival (*p*-value 9.9 × 10^−3^) but not independently of *IGHV* status (*p*-value 0.24). Amplifications in *IRF4* were associated with shorter survival (*p*-value 6.4 × 10^−5^) in a partially *IGHV*-independent manner (*p*-value 0.025). Nevertheless, this finding must be interpreted with caution due to the position of *IRF4* near the telomeric end of the short arm of chromosome 6.

Correlation of Focal CNAs With Gene Expression {#s3_2}
----------------------------------------------

We detected significant correlations between some recurrent CNAs and their correspondingly encoded genes ([**Supplementary Table 2**](#SM3){ref-type="supplementary-material"}). As expected, deletions in 11q22.3 and 13q14.2 and the expression of their respective genes (*ATM, FDX1*, and *RDX* in the first case, and *DLEU1, DLEU2*, and *KCNRG* in the second case). Deletions in 6q21 were correlated with lower expression of *CDK19*, and so did those in 14q21.1 with the expression of *MIA2*. Furthermore, we detected significant correlations between amplifications in 3q25.1 and 3q29 and expression of their target genes *PFN2* and *ACAP2*, respectively. Surprisingly, an inverse correlation was observed between 11q14.3 deletions and *FOLH1B* expression.

Similarly, we detected significant correlations between 19 of these CNAs and the expression of 926 protein-coding genes (*q*-value \< 0.01; [**Supplementary Table 3**](#SM4){ref-type="supplementary-material"}). The CNAs with more correlated genes were deletions in 13q14.2 (389 genes), 12q24.33 (*ULK1* locus, 170 genes), 6q21 (*CDK19* locus, 79 genes), 11q22.3 (*ATM* locus, 39 genes), and 3q25.33 (*IL12A* locus, 26 genes), as well as amplifications in 18q22.1 involving *TMX3* (135 genes).

Nonetheless, this study is probably underpowered to detect CNA--transcript correlations due to the fact that only 50% of the exome-seq samples had matched RNAseq data of purified CLL cells.

Broad CNA Regions and Their Association With Clinical Evolution {#s3_3}
---------------------------------------------------------------

Recurrent broad amplifications and deletions were detected in the CLL genome ([**Table 3**](#T3){ref-type="table"}, [**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Among the amplifications, the most frequent were found in chromosomes 12 (60 cases, 13.6% of patients), 2p (10 patients), 8q (6 patients), 18q (6 patients), 18p (5 patients), and 3q (5 patients). Similarly, the most recurrent large deletions were detected in 17p (8 patients), 18p (7 patients), and 8p (6 patients).

###### 

Significantly enriched broad cytogenetic aberrations in the chronic lymphocytic leukemia (CLL) genome.

  Arm   Genes   Amp frequency   Amp frequency score   Amp z-score   Amp q-value   Del frequency   Del frequency score   Del z-score   Del q-value
  ----- ------- --------------- --------------------- ------------- ------------- --------------- --------------------- ------------- -------------
  1p    2,121   0               0                     −0.613        0.92          0               0                     −0.613        0.93
  1q    1,955   0               0                     −0.729        0.92          0               0                     −0.729        0.93
  2p    924     0.02            0.02                  6.99          1.81E−11      0               0                     0.446         0.93
  2q    1,556   0               0                     1.16          0.48          0               0                     0.106         0.93
  3p    1,062   0               0                     0.543         0.83          0               0                     −1.17         0.93
  3q    1,139   0.01            0.01                  3.26          3.59E−03      0               0                     −1.13         0.93
  4p    489     0               0                     −1.38         0.92          0               0                     0.0708        0.93
  4q    1,049   0               0                     0.53          0.83          0               0                     −1.17         0.93
  5p    270     0               0                     −0.0742       0.92          0               0                     −1.45         0.93
  5q    1,427   0               0                     0.965         0.59          0               0                     −1.01         0.93
  6p    1,173   0               0                     −1.13         0.92          0               0                     −1.13         0.93
  6q    839     0               0                     −1.25         0.92          0.01            0.01                  1.14          0.67
  7p    641     0               0                     −1.33         0.92          0               0                     −0.574        0.93
  7q    1,277   0               0                     −0.151        0.92          0               0                     −0.151        0.93
  8p    580     0               0                     0.155         0.92          0.01            0.01                  3.12          0.01
  8q    859     0.01            0.01                  3.58          1.36E−03      0               0                     −0.433        0.93
  9p    422     0               0                     −1.4          0.92          0.01            0.01                  0.74          0.93
  9q    1,113   0               0                     −1.15         0.92          0               0                     0.594         0.93
  10p   409     0               0                     −1.41         0.92          0               0                     −1.41         0.93
  10q   1,268   0               0                     −1.08         0.92          0               0                     −1.08         0.93
  11p   862     0               0                     −0.442        0.92          0               0                     −0.442        0.93
  11q   1,515   0               0                     −0.969        0.92          0               0                     1.09          0.67
  12p   575     0.14            0.14                  43.2          0             0               0                     −1.26         0.93
  12q   1,447   0.14            0.14                  58.9          0             0               0                     −0.933        0.93
  13q   654     0               0                     −1.32         0.92          0               0                     −1.32         0.93
  14q   1,341   0               0                     −1.05         0.92          0               0                     −0.1          0.93
  15q   1,355   0               0                     −0.0881       0.92          0               0                     −1.05         0.93
  16p   872     0               0                     −1.24         0.92          0               0                     −0.439        0.93
  16q   702     0               0                     −1.31         0.92          0               0                     −0.54         0.93
  17p   683     0               0                     −1.3          0.92          0.02            0.02                  4.8           3.16E−05
  17q   1,592   0               0                     0.144         0.92          0               0                     1.22          0.67
  18p   143     0.01            0.01                  1.9           0.12          0.02            0.02                  3.24          0.01
  18q   446     0.01            0.01                  2.92          9.84E−03      0               0                     −1.39         0.93
  19p   995     0.01            0.01                  2.16          0.07          0               0                     0.492         0.93
  19q   1,709   0.01            0.01                  3.73          9.33E−04      0               0                     1.44          0.64
  20p   355     0               0                     −0.714        0.92          0.01            0.01                  1.39          0.64
  20q   753     0               0                     −0.51         0.92          0               0                     −1.29         0.93
  21q   509     0.01            0.01                  0.823         0.67          0               0                     0.0945        0.93
  22q   921     0               0                     −1.22         0.92          0               0                     0.411         0.93

Amplifications in chromosomes 12, 2p, and 8q, as well as deletion of 17p, were significantly associated with shorter TTT ([**Supplementary Tables 4**](#SM5){ref-type="supplementary-material"} and [**5**](#SM6){ref-type="supplementary-material"}). Furthermore, deletion of 17p was significantly associated with TTT independently of *IGHV* status, sex, and Binet staging. Amplifications in chromosomes 12 and 8q were associated with shorter OS, but no event was significant after adjusting for *IGHV* status, age, and Binet staging. Nonetheless, we detected a significant difference in OS and TTT between *IGHV*-mutated cases with and with and without trisomy 12 ([**Figures 3A, B**](#f3){ref-type="fig"} respectively).

![Probability of treatment need **(A)** and survival **(B)** for trisomy 12-negative patients with mutated *IGHV* (red line), trisomy 12-positive patients with mutated *IGHV* (blue line), trisomy 12-negative patients with unmutated *IGHV* (green line), and trisomy 12-positive patients with unmutated *IGHV* patients (purple line).](fgene-10-00854-g003){#f3}

Regions of CNN-LOH {#s3_4}
------------------

Control-FREEC identified 63 regions of CNN-LOH with a genotype uncertainty below 5% ([**Supplementary Table 6**](#SM7){ref-type="supplementary-material"}). Ten events were located at 1p, six of which affected *ARID1A*. By comparing with mutation data published by [@B36], none of these samples bore concurrent non-synonymous mutations in *ARID1A*. Other three events were detected at 1q, with a minimally affected region on 1q21.3, which holds likely driver genes such as *PI4KB* and *IL6R/CD126*. Four CNN-LOH events with a minimally involved region in 9q34.13--q34.3 involved the *NOTCH1* gene. One of these cases also had a frameshift deletion in *NOTCH1*. Three events at 11p15.5--15.4 affected the imprinted locus of *IGF2* and *CDKN1C*. Eight CNN-LOH events affected the 11p11.2--q13.2 region. Two different samples had events at 11q involving the *ATM* locus, both of which also had non-synonymous *ATM* mutations. Three events were located in 16p13.3--p13.11, which involve the *CREBBP* gene. None of these had mutations in *CREBBP*. Ten CNN-LOH events affected chromosome 17, three of which included the *TP53* locus. Among the latter, two had non-synonymous mutations in *TP53*. Four samples had CNN-LOH events at chromosome 20, all of which affect the *ASXL1* gene but without any concurrent mutation in it. It is interesting to mention that only two of the CNN-LOH events overlapped with those reported by [@B36] using SNP array technology.

Discussion {#s4}
==========

The detection of new cytogenetic aberrations using targeted sequencing takes advantage of the increased sensitivity of this technique in order to detect small events that would be otherwise difficult to identify using array-based techniques. CLL is characterized by large-scale cytogenetic alterations ([@B10]), but focal rearrangements have been studied to a lower extent. Using sequencing data originally produced by [@B36], here, we report the existence of 54 putatively recurrent focal CNAs in the CLL genome.

Recurrent focal amplifications were shorter than deletions, mostly involving one or two genes. The most significantly enriched focal gains affected the loci of *SUZ12, WT1, HFM1, RFWD2, FLT4*, and *TTNI3K*. On the contrary, focal deletions were wider and tended to span more than two genes. As expected, among the most significant deletions were those in 13q14.2 and in 11q22.3. Nevertheless, other highly significant regions involved the loci of genes such as *NOX4*, a component of the NADPH oxidase complex ([@B13]), and *MIA2*, a tumor suppressor gene ([@B14]). Deletions in *SETD2*, 11q22.3, and 14q32.33 were associated with shorter time to first treatment, and gains of *IRF4* were independently associated with short survival. Furthermore, we could detect significant positive correlations between six recurrent CNAs and the expression of genes encoded in their respective loci, as well as correlations between 19 CNAs and the expression 926 protein-coding genes genome wide.

Focal recurrent gains and losses tended to target genes that participate in oncogenic pathways. For example, five amplified genes (*HFM1, ANAPC10, TAF5, COBRA1*, and *SYCE3*) and one deleted gene (*FAM175A/ABRAXAS*) are involved in DNA transcription, replication, and repair mechanisms. Both *COBRA1* and *FAM175A* physically interact with the tumor suppressor *BRCA1* ([@B7]; [@B49]), whereas *ANAPC10* belongs to the anaphase-promoting complex/cyclosome family of proteins that control sister chromatid segregation and cytokinesis ([@B8]). The amplified genes *PHF21A*, *PCGF6*, and *SUZ12* encode epigenetic regulators with repressor activity ([@B17]; [@B46]; [@B52]). Other genes targeted by recurrent events participate in important pathways. This is the case of the amplified oncogenes *AKT1* ([@B16]) and *WT1* ([@B1]), and of the receptor tyrosine kinase gene *FLT4*, which regulates lymphangiogenesis and tumor metastasization to lymphatic vessels ([@B23]). Likewise, the deleted genes *AMD1, TP53INP1, ULK1*, and *NFATC1* are also important in tumorigenesis. *AMD1* and *TP53INP1* participate in metabolic pathways, and both have tumor suppressor activity ([@B43]; [@B42]), whereas *ULK1* plays a decisive role in autophagy initiation ([@B50]) and *NFATC1* maintains an anergic phenotype in CLL cells ([@B29]). Finally, two cyclin-dependent kinase genes were recurrently deleted: *CDK6* and *CDK19*. Deletions in *CDK6* were associated with shorter time to first treatment, whereas those in *CDK19* were correlated with a reduced expression of the gene. *CDK19* is a component of the mediator kinase module, which associates with the mediator complex in order to regulate diverse cellular functions ([@B9]), and *CDK6* is a promoter of cell-cycle progression ([@B20]). The role of both genes in the pathogenesis of CLL needs further clarification.

Finally, recurrent broad cytogenetic aberrations characteristic of CLL were identified at the expected frequency, as in the case of trisomy 12, 17p deletion, amplification of 8q, and loss of 8p ([@B3]). Interestingly, we detected a significant adverse time to event and OS effect of trisomy 12 among *IGHV*-mutated cases. The importance of *IGHV* mutation as a predictor of disease evolution within the group of patients with trisomy 12 was previously reported by others ([@B6]; [@B41]), but to our knowledge, this is the first report about the prognostic importance of trisomy 12 among *IGHV*-mutated cases. Furthermore, new CNN-LOH events affecting CLL drivers were also detected, most of which had not been described in previous array-based analysis of the CLL genome ([@B34]; [@B35]). These CNN-LOH events affected the *ATM, NOTCH1, TP53, ARID1A, ASXL1, CREBBP*, and *PI4KB/IL6R* loci, as well as the telomeric region of 11p. Only part of these mutations had concurrent mutations in their corresponding driver genes, suggesting the existence of other mechanisms of pathogenicity.

Detection of copy number changes based on exome-sequencing has been proven to be prone to false positives by some studies ([@B40]). In this analysis, we have included patient matched control samples, we applied stringent thresholds in order to minimize false detections, and we recapitulated most of the cytogenetic findings of CLL in the expected frequency. Furthermore, we could correlate the presence of this structural aberrations with changes in gene expression in a subgroup of patients, although we believe that this study may be underpowered to detect such associations.

In conclusion, our study presents proof-of-concept evidence for the existence of new focal recurrent CNAs and CNN-LOH in the genome of CLL, some of which influence clinical outcome. Furthermore, we observed that some of these novel events have significant correlations with gene expression changes. The results are concordant with the possible involvement of a set of oncogenes and tumor suppressors in the development of CLL. These results should be considered a "proof of concept," and their existence and functionality should be validated in the future.
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Association of focal amplifications and deletions with TTT and OS. Only those events affecting at least 5 patients of this cohort were selected for the analysis.
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Significant correlations detected between CNA events and expression of genes encoded in their respective loci.
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Significant correlations detected between CNA events and any protein-coding genes genome-wide (q-value \<0.01).
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Association of large-scale deletions with TTT and OS. Only those events affecting at least 5 patients of this cohort were selected for the analysis.
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Association of large-scale amplifications with TTT and OS. Only those events affecting at least 5 patients of this cohort were selected for the analysis.

###### 

Click here for additional data file.

###### 

Summary of the detected LOH events detected, along with candidate gene annotation and its mutation status in the data published by *Puente et al*.
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